<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05039931</url>
  </required_header>
  <id_info>
    <org_study_id>GNC-035-101(V1.1)</org_study_id>
    <nct_id>NCT05039931</nct_id>
  </id_info>
  <brief_title>A Study of GNC-035, a Tetra-specific Antibody, in Participants With Locally Advanced or Metastatic Solid Tumors</brief_title>
  <official_title>An Open-Label, Multi-Center, Phase I Study to Evaluate the Safety, Tolerability，Pharmacokinetic/Pharmacodynamics and Anti-tumor Activity of Tetra-specific Antibody GNC-035 in Participants With Locally Advanced or Metastatic Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sichuan Baili Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>SystImmune Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sichuan Baili Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, the safety, tolerability and preliminary effectiveness of GNC-035 in&#xD;
      participants with locally advanced or metastatic solid tumors will be investigated to assess&#xD;
      the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) or maximum administered dose&#xD;
      (MAD) for MTD is not reached of GNC-035.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 8, 2021</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>DLT</measure>
    <time_frame>Up to 2 weeks</time_frame>
    <description>Dose limiting toxicity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MTD or MAD</measure>
    <time_frame>Up to 2 weeks</time_frame>
    <description>Maximum tolerated dose or maximum administrated dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>TEAE</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Treatment-Emergent Adverse Event</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The recommended dose for future clinical study</measure>
    <time_frame>Up to 2 weeks</time_frame>
    <description>The recommended dose for future clinical study</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AESI</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Adverse Events of special interest</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>Up to 2 weeks</time_frame>
    <description>Maximum serum concentration of GNC-035</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>Up to 2 weeks</time_frame>
    <description>Time to maximum serum concentration (Tmax) of GNC-035</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1/2</measure>
    <time_frame>Up to 2 weeks</time_frame>
    <description>Half-life of GNC-035</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and titer of ADA</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Anti-drug antibody</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Objective Response Rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DCR</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Disease Control Rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Progression-free Survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DOR</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Duration of Response</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">29</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Solid Tumor</condition>
  <arm_group>
    <arm_group_label>GNC-035</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive GNC-035 as a 24-hour continuous intravenous infusion (cIV, QD) for 2 weeks (a 2-week cycle). Participants with no intolerable AEs could continue for another three cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GNC-035</intervention_name>
    <description>Administration by intravenous infusion.</description>
    <arm_group_label>GNC-035</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. The participants could understand and sign the informed consent form, and must&#xD;
             participate voluntarily&#xD;
&#xD;
          2. No gender limit&#xD;
&#xD;
          3. Age: ≥18 years old&#xD;
&#xD;
          4. Histologically or cytologically documented, locally advanced or metastatic solid&#xD;
             tumour,and disease progression confirmed by imaging or other objective evidence after&#xD;
             having received standard treatment; or patients with refractory solid tumors who&#xD;
             cannot tolerate standard treatment or have contraindications to standard treatment&#xD;
&#xD;
          5. Measurable disease at baseline as assessed by the Investigator per RECIST v1.1&#xD;
&#xD;
          6. ECOG Performance Status ≤ 1&#xD;
&#xD;
          7. Life expectancy estimated to be at least 3 months&#xD;
&#xD;
          8. Acceptable bone marrow function： Absolute neutrophil count (ANC) ≥ 1.5 × 109/L,&#xD;
             platelet count ≥ 80 × 109/L, and hemoglobin ≥ 90 g/L.&#xD;
&#xD;
          9. Acceptable renal function:&#xD;
&#xD;
             Creatinine (Cr) ≤ 1.5ULN or creatinine clearance (Ccr) ≥ 50 mL/min (calculated by the&#xD;
             study site), urine protein ≤ 2 + or ≤ 1000 mg/24h (urine).&#xD;
&#xD;
         10. Acceptable liver function:&#xD;
&#xD;
             AST and ALT ≤ 3.0xULN (≤ 5.0ULN for patients with tumor infiltrative changes in the&#xD;
             liver) total bilirubin ≤ 1.5xULN (≤ 3ULN for Gilbert's syndrome)&#xD;
&#xD;
         11. Coagulation function: fibrinogen ≥ 1.5 g/L, activated partial thromboplastin time&#xD;
             (APTT) and prothrombin time (PT) ≤1.5×ULN&#xD;
&#xD;
         12. Female participants with fertility or male participants whose partner(s) are fertile&#xD;
             must take effective contraceptive measures from 7 days prior to the first&#xD;
             administration to 12 weeks after the administration. Female participants with&#xD;
             fertility must have a negative serum/urine pregnancy test in 7 days prior to the first&#xD;
             dose.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Active infection requiring intravenous antibiotics and not treated within 1 week prior&#xD;
             to enrollment, except for prophylactic antibiotics for needle stick or biopsy&#xD;
&#xD;
          2. Human immunodeficiency virus antibody (HIVAb) positive, active tuberculosis, active&#xD;
             hepatitis B virus infection (HBsAg positive or HBcAb positive with HBV-DNA detection ≥&#xD;
             10e4), or hepatitis C virus infection (HCV antibody positive with HCV-RNA ≥ ULN)&#xD;
&#xD;
          3. Toxicity from prior anticancer therapy has not been reduced to Grade I as defined in&#xD;
             CTCAE v5.0 (with the exception of symptoms related to myelosuppression, such as&#xD;
             neutropenia, anemia, thrombocytopenia) or to the levels specified in the inclusion&#xD;
             criteria. Alopecia and irreversible toxicity from prior anticancer therapy (defined as&#xD;
             stable for ≥ 2 months) allowed in the opinion of the investigator/sponsor; irAE in&#xD;
             patients who have received prior immunotherapy and who are no longer able to receive&#xD;
             immunotherapy as recommended by guidelines&#xD;
&#xD;
          4. Patients at risk for active autoimmune diseases, or with a history of autoimmune&#xD;
             diseases, may have central nervous system involvement, including but not limited to&#xD;
             Crohn's disease, ulcerative colitis, systemic lupus erythematosus, sarcoidosis,&#xD;
             Wegener's syndrome, polyangitic granulomatosis, Graves' disease, rheumatoid arthritis,&#xD;
             hypophysitis, uveitis, autoimmune hepatitis, systemic sclerosis, Hashimoto's&#xD;
             thyroiditis, autoimmune vasculitis, autoimmune neuropathy (Guillain - Barré syndrome),&#xD;
             etc.&#xD;
&#xD;
          5. Pulmonary disease defined as ≥ Grade 3 according to NCI-CTCAEv5.0, including patients&#xD;
             with resting dyspnea, or requiring continuous oxygen therapy, or with a history of&#xD;
             interstitial lung disease (ILD)&#xD;
&#xD;
          6. Patients with prior organ transplant&#xD;
&#xD;
          7. Left ventricular ejection fraction ≤ 50%, or history of significant cardiac disease&#xD;
             within 1 year&#xD;
&#xD;
          8. History or presence of thrombotic events such as deep venous thrombosis, arterial&#xD;
             thrombosis, and pulmonary embolism&#xD;
&#xD;
          9. Received chemotherapy, molecular targeted therapy, etc., at 14 or 5 half-lives&#xD;
             (whichever is shorter) of the first dose. Patients who have received radiotherapy,&#xD;
             antibody therapy (such as PD-L1) or study drug within 28 days&#xD;
&#xD;
         10. Patients who had undergone major surgery within 28 days prior to dosing in this study,&#xD;
             or who were scheduled to undergo major surgery during this study (&quot;major surgery&quot;was&#xD;
             defined by the investigator)&#xD;
&#xD;
         11. Hypertension poorly controlled on medication (systolic &gt; 150 mmHg or diastolic &gt; 100&#xD;
             mmHg)&#xD;
&#xD;
         12. Previous or concomitant central nervous system disease&#xD;
&#xD;
         13. Has receivedany other clinical trial within 4 weeks prior to GNC-035 treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yongsheng Wang</last_name>
    <role>Principal Investigator</role>
    <affiliation>West China Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hai Zhu</last_name>
    <phone>+86-13980051002</phone>
    <email>zhuhai@baili-pharm.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sa Xiao</last_name>
    <phone>+86-15013238943</phone>
    <email>xiaosa@baili-pharm.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>West China Hospital of Sichuan University</name>
      <address>
        <city>Sichuan</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yongsheng Wang</last_name>
      <phone>+86-028-85429455</phone>
      <email>wangys75@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Yunyun Zhao</last_name>
      <phone>+86-028-85422654</phone>
      <email>huaxilunli@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Yongsheng Wang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 22, 2021</study_first_submitted>
  <study_first_submitted_qc>September 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2021</study_first_posted>
  <last_update_submitted>September 7, 2021</last_update_submitted>
  <last_update_submitted_qc>September 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast Cancer</keyword>
  <keyword>Lung Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

